OptiNose
Yardley, US · Delaware corporation · 2 known investors
Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists. Its lead product, XHANCE (fluticasone propionate), uses the company's patented Bi-Directional Exhalation Delivery System (EDS) to deliver medication deep into the nasal passages.
Founders & leadership
PD
Per DjupeslandFounder
MJ
Michele JanisExecutive
PM
Peter MillerExecutive
TT
Terrence TerifayExecutive
RM
Ramy MahmoudExecutive
Board
KD
Klaas De BoerBoard director
SV
Sriram VenkataramanBoard director
WF
William F DoyleBoard director
JP
Jackson PhillipsBoard director
LP
Larry PickeringBoard director
PO
Patrick O'NeillBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$99.4M disclosed across 7 rounds · 2014–2024
▶$4.7MraisedMay 2024 · 2 investors · PharmaceuticalsRule 506(b)
▶$4.7MraisedMay 2024 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul SpenceExecutive Officer
- Catherine E. OwenDirector
- Wilhelmus GroenhuysenDirector
- Eric BednarskiDirector
- Tomas J. HeymanDirector
- Sandra L. HeltonDirector
- Kyle DempseyDirector
- Ramy A. MahmoudDirector, Executive Officer
- Michael F. MarinoExecutive Officer
- R. John FletcherDirector
- Anthony J. KrickExecutive Officer
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedNov 2021 · 2 investors · PharmaceuticalsRule 506(b)
▶$4MraisedNov 2021 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter K. MillerExecutive Officer, Director
- Michael F. MarinoExecutive Officer
- Wilhelmus GroenhuysenDirector
- Keith GoldanExecutive Officer
- Tomas J. HeymanDirector
- Catherine E. OwenDirector
- Ramy A. MahmoudExecutive Officer
- Victor M. ClavelliExecutive Officer
- Joseph C. ScodariDirector
- Sandra L. HeltonDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedAug 2020 · 2 investors · PharmaceuticalsRule 506(b)
▶$250KraisedAug 2020 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Victor ClavelliExecutive Officer
- Joshua A. TamaroffDirector
- Michael F. MarinoExecutive Officer
- Sriram VenkataramanDirector
- William F. DoyleDirector
- Joseph C. ScodariDirector
- Ramy A. MahmoudExecutive Officer
- Robert P. O'NeilDirector
- Sandra L. HeltonDirector
- Keith GoldanExecutive Officer
- Wilhelmus GroenhuysenDirector
- Catherine E. OwenDirector
- Peter K. MillerExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedSep 2019 · 2 investors · PharmaceuticalsRule 506(b)
▶$5.4MraisedSep 2019 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ramy A. MahmoudExecutive Officer
- Michael F. MarinoExecutive Officer
- Sriram VenkataramanDirector
- Robert P. O'NeilDirector
- Sandra L. HeltonDirector
- Wilhelmus GroenhuysenDirector
- William F. DoyleDirector
- Joseph C. ScodariDirector
- Keith GoldanExecutive Officer
- Peter K. MillerExecutive Officer, Director
- Joshua A. TamaroffDirector
- Offering amount
- $5.4M
- Amount sold
- $5.4M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedApr 2017 · 8 investors · Other Health CareRule 506(b)
▶$35MraisedApr 2017 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joshua TamaroffDirector
- Patrick O'NeillDirector
- William F. DoyleDirector
- Ramy MahmoudExecutive Officer
- Keith GoldanExecutive Officer
- Peter MillerExecutive Officer, Director
- Michael MarinoExecutive Officer
- Klaas De BoerDirector
- Per DjupeslandDirector
- Larry PickeringDirector
- Tom GibbsExecutive Officer
- Sriram VenkataramanDirector
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedOct 2015 · 23 investors · Other Health CareRule 506(b)
▶$35MraisedOct 2015 · 23 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Per DjupeslandExecutive Officer, Director
- Michele JanisExecutive Officer
- Larry PickeringDirector
- Patrick O'NeillDirector
- Peter MillerExecutive Officer, Director
- Klaas De BoerDirector
- Terrence TerifayExecutive Officer
- Sriram VenkataramanDirector
- William F DoyleDirector
- Ramy MahmoudExecutive Officer
- Jackson PhillipsDirector
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedOct 2015 · 21 investors · Other Health CareRule 506(b)
▶$15MraisedOct 2015 · 21 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Larry PickeringDirector
- Patrick O'NeillDirector
- Ramy MahmoudExecutive Officer
- Terrence TerifayExecutive Officer
- Peter MillerDirector, Executive Officer
- Jackson PhillipsDirector
- Sriram VenkataramanDirector
- William F. DoyleDirector
- Klaas De BoerDirector
- Per DjupeslandExecutive Officer, Director
- Michele JanisExecutive Officer
- Offering amount
- $30M
- Amount sold
- $15M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapOsmosis797 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.
Medscape755 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Companies competing with OptiNose for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does OptiNose do?
- Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists. Its lead product, XHANCE (fluticasone propionate), uses the company's patented Bi-Directional Exhalation Delivery System (EDS) to deliver medication deep into the nasal passages.
- Who founded OptiNose?
- OptiNose was founded by Per Djupesland.
- Who are OptiNose's investors?
- OptiNose's investors include Foresite Capital, MVM Life Science Partners.
- How much funding has OptiNose raised?
- OptiNose has disclosed $99.4M raised across 7 rounds.
- Where is OptiNose headquartered?
- OptiNose is headquartered in Yardley, US.